Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Valeo Pharma Inc - Class A T.VPH

Alternate Symbol(s):  VPHIF | T.VPH.W.A | T.VPH.W | T.VPH.DB

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its products include Benztropine, Synacthen, M-Eslon, and others.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Commercializing Innovative Prescription Products in Canada

Watch Valeo's presentation shortly. They are up at 10:30am PT / 1:30pm ET.  Here's the link to tune in    rate and reply

new video

  rate and reply

TSX update 4:59

  rate and reply

Q1-2022 Webcast and Conference Call

Valeo will host a conference call to discuss its first quarter 2022 results and highlights on Friday March 25, 2022 at 8.30am (ET). The telephone numbers to access the conference more



Q1-22 revenues of $4.2 million, up 128% over Q1-21   Q1-22 gross margins of $1.4 million, up 266% over Q1-21   Public reimbursement secured in key provinces more

Yesterrday interview

  rate and reply

What happened?

Can anyone figure out why there was a 15% drop today on exceptional daily volume? I've been looking and so far only found a poorly done article by Simply Wall Street from this morning.  rate and reply

Webinar Recap w Radius Research and $VPH CEO Steve Saviuk

Webinar Recap: Valeo Pharma (VPH) w CEO Steve Saviuk - Commercializing Innovative Prescription Products in Canada - Pitch, Deep Dive and Q&A - { more

VPH: Strong year-end results today!

This morning, Valeo Pharma published  RECORD ANNUAL REVENUES FOR FISCAL 2021! Trading at 66 cents, VPH is way undervalued and is a potential double with strong prospect for more

financial results  rate and reply


The year end financials are out on Sedar.  rate and reply

Webinar w VPH CEO Steve Saviuk - Tue, Mar 1 @ 12:30PM ET

Webinar - Valeo Pharma (VPH) w/ CEO Steve Saviuk Tue, Mar 1 at 12:30pm ET / 9:30am PT Q&A with Radius Research  Register Here - more


Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC") more


Yeah something weird is going on. I hope Fidelity drives the price up. I have 22,000 warrants currently that I'd like to use to buy shares rather than exercise them at $1.50 with a share price more


I also bought some shares and the same happened. There seems to be an arrangement within a few brokage firms to keep it low.  Fidelity has several warrents. They will drive it up starting more


When will management have things in place to get on the TSX. This is sickening. I bought more shares today. Not much but still increasing my holdings so still trying to buy 1000 shares at least once more

RE:VPH: VALEO PHARMA offers COVID-19 product for immune support

sweet  rate and reply

Debt Free

New to this company, is VPH dept free?  rate and reply

VPH: VALEO PHARMA offers COVID-19 product for immune support

Please read this very important news that should be very beneficial for VPH shareholders. The new product: HESPERCO • Clinical study yields encouraging results that hesperidin may help more
The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >